The study analyzed the impact of EGFR and ALK mutations on patient outcomes, revealing that although the p-values did not reach statistical significance (p = 0.084 for EGFR and p = 0.255 for ALK), the observed values and cumulative survival probabilities suggest the potential influence of these genetic alterations on NSCLC prognosis. Here, ALK is linked to non-small cell lung carcinoma.